1 Department of Diabetes and Vascular Medicine, Peninsula Medical School, Exeter, U.K
2 Wellcome Trust Centre for Human Genetics, Oxford, U.K
3 Department of Diabetes and Metabolic Medicine, St. Bartholomews and the Royal London, Queen Marys School of Medicine & Dentistry, London, U.K
4 Department of Medicine, Medical School, University of Newcastle, Newcastle, U.K
5 Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K
6 Elsie Bertram Diabetes Centre, Norfolk and Norwich, University Hospital, Norwich, U.K
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
For many complex diseases, genetic predisposition is stronger in subjects diagnosed at younger ages. There is evidence that this is true in type 2 diabetes. Younger type 2 diabetic subjects show increased familial clustering of diabetes even when monogenic forms are excluded. Several studies have shown high prevalences of parental diabetes in subjects diagnosed at young ages (13). Weijnen et al. (4) demonstrated that younger age at diagnosis (AAD) results in an increased relative risk to siblings. This is likely to reflect increased genetic predisposition as well as shared environmental factors.
If type 2 diabetic patients diagnosed at a young age have a stronger genetic predisposition, two questions need to be answered: 1) do these patients have a different genetic predisposition? and 2) are patients diagnosed at young ages more heavily loaded for the predisposing genes that contribute to disease across all ages? The answers to these questions will be crucial in refining strategies for type 2 diabetes gene discovery.
If subjects diagnosed at younger ages have a stronger genetic predisposition, it is then likely that they provide a more powerful resource for mapping susceptibility genes. The hypothesis that families segregating young-onset diabetes are a more powerful resource for mapping genes compared with families with patients diagnosed from across all age ranges has not been tested using genome-wide genotype data. In some studies, such as FUSION (5), subjects diagnosed young contribute disproportionately to the evidence for linkage at some loci. However, these previous studies did not present the evidence for linkage from young-onset families from across all the genome.
To examine the hypothesis that young-onset families are a more powerful resource for mapping genes, and to define whether the localization of predisposing genes in these families was similar or different to that found in all subjects, we used the Diabetes UK Warren 2 sibling pair collection. A recent genome-wide scan using 573 of these families revealed seven putative loci on chromosomes 1, 5, 7, 8, and 10 (6). None of these loci reached genome-wide levels of significance when using the Lander and Kruglyak guidelines (7), which, though widely used, assume that complete genetic information has been extracted from the families. However, as the majority of type 2 diabetes sibling pairs do not have parents available, and because our genome scan had a mean marker spacing of 9 cM, such assumptions are not appropriate. Instead, genome-wide significance levels were determined empirically from the data. In addition, a recent study applied a complementary approach to assess results from the Diabetes UK Warren 2 genome scan (8). Simulations of the genome scan (using the same family structures, maps, and allelic frequencies) were performed under the null hypothesis of no linkage and were then compared with the observed number of loci showing evidence for linkage with the number expected under the null hypothesis of no linkage. The results showed there were more loci with evidence for linkage than expected by chance, even though it was not possible to determine which loci were real and which signals had appeared through stochastic variation.
In this study, we have examined subsets of young AAD sibpair families from the Warren 2 genome scan. We have tested whether younger families contribute disproportionately to the evidence for linkage at loci identified in our overall scan and whether they provide evidence for additional loci.
![]() |
RESEARCH DESIGN AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Subsets.
We reanalyzed our genome-wide scan on three subsets of families according to defined AAD cutoffs. These subsets were selected to have an average AAD in affected family members of <45.0 (L45) and <55.0 (L55) years. These represented the youngest 39 (7%) and 245 (43%) families, respectively. The subsets were not exclusive, so all members of the L45 subset were also in the L55 subset. In addition to the sibships, DNA was available from two affected and one unaffected parents in the L45 subset and from six affected and six unaffected parents in the L55 subsets. In addition, to assess the contribution of young AAD families to the evidence for linkage, we analyzed the complementary 328 families with an average AAD ≥55 years (G55). Clinical characteristics of affected subjects from these subsets are given in table one along with details of the total dataset for comparison. In addition, because of its potential relevance to increased genetic susceptibility, we calculated the proportion of subjects with a recalled maternal or paternal history of diabetes. No subjects had a bilineal parental history of diabetes, as this was an exclusion criterion. To minimize bias, we only included data from probands who recalled the diabetes status of both parents. There was no difference in the proportion of subjects recalling the diabetes status of both parents across subsets (90% in all groups). Fishers exact test and
2 test for trend were used to compare frequencies of parental diabetes between groups.
Linkage analysis.
Linkage analyses were performed using the genotype data generated from the 573 families as previously reported (6). Briefly, this included 418 autosomal microsatellite markers genotyped on ABI-377 platforms. These markers had an average spacing of 9 Haldane centiMorgans [cM (H)]. To eliminate bias toward loci identified in the overall scan, we did not include the extra markers used to fine map the region identified on chromosome 1q. Analysis was performed exactly as described in the analysis of the 573 sibships: a Haldane map function was used and multipoint model free linkage statistics (the allele-sharing logarithm of odds [LOD] score of Kong and Cox [9]) computed using ALLEGRO version 1.1b [10]). All LOD scores are multipoint.
Significance of individual young AAD loci.
To compare the evidence for linkage obtained in each subset with that obtained from the total analysis, we used permutation methods to derive empirical significance values for any differences in LOD score observed. For each replicate, we selected either 39 or 245 families (equivalent to the numbers of pedigrees in the L45 and L55 subsets, respectively) at random from the 573 family dataset and determined the LOD score. With 10,000 replicates, we were able to establish the frequency with which this selection led to an increase in LOD score equivalent to or greater than that detected in the observed data. The number of times the actual LOD was reached or exceeded (within 20 cM of either side of the observed peak) was then used to calculate an empirical P value for the effects of subsetting. Any increase in the evidence for linkage in the young families was not due to the extraction of extra information from these families. Average family size, as assessed by numbers of affected subjects, and information extraction were identical across the L45, L55, and G55 subsets (data not shown).
Ordered subset analysis.
As a complementary analysis to those based on predetermined age cutoffs (L45 and L55), we performed ordered subset analyses at each locus. This method can be used for any quantitative trait. It attempts to reduce the likely genetic heterogeneity underlying type 2 diabetes by identifying more homogeneous groups of families on the basis of diabetes-associated intermediate traits. This method was used in analyses by the FUSION study (5). We used mean AAD to rank all 573 families from youngest to oldest and, in a separate analysis, oldest to youngest. The LOD score for linkage to type 2 diabetes was then repeatedly recalculated as families were added in rank order. The overall maximum LOD score for any subset of families is reported. The significance of this maximized LOD score derived from these analyses was assessed by 10,000 permutations adding in families in random order.
Estimation of expected numbers of independent regions of linkage.
To gain a better understanding of the strength of evidence for linkage obtained from each subset, we compared the results from the subset genome scans with results expected under the null hypothesis of no linkage using previously described methods (8). Briefly, using SIMULATE (11), 10,000 replicates of the genome were simulated under the null hypothesis of no predisposing loci, assuming no latent genotyping error, using the same map and allele frequencies applied for the 573 families and the same pattern of missing genotype information observed in the subsets of families. Each replicate was then analyzed using ALLEGRO and IRLs, defined as maximum LOD scores >55 cM(H) apart (40 cM[K]), counted. To assess the significance of the observed number of loci obtained from across the range of LOD score thresholds compared with the number of loci expected under the null hypothesis of no linkage, we also determined from our simulations the number of independent regions of linkage (IRLs) with a cumulative probability of 0.95 and 0.99. These probabilities are equivalent to a one-tailed P value of 0.05 and 0.01, respectively.
The locus-counting plots in Fig. 1 graphically represent the genome-wide number of independent regions showing evidence for linkage (i.e., independent loci). These plots show the number of IRLs observed in an actual genome-wide scan experiment, in relation to the number expected by chance under the null hypothesis of no linkage at all, across the whole range of feasible LOD score thresholds. Each point for the null IRL distribution represents the mean count of IRLs per genome scan, estimated from 10,000 replicates of the genome under the null, that meet or exceed the given LOD score threshold. The actual IRL distribution trace shows the analogous counts observed in the actual genome scan experiment itself: as it is based on one single experiment, it has a step-like appearance. Any excess of loci observed in the actual genome scan, over that expected by chance under the null, can be clearly visualized from these traces. Each point on the P = 0.05 limit trace represents the number of IRLs, at the given LOD threshold, that must be met or exceeded in the actual genome scan for the excess to be significant at the P = 0.05 significance limit. As only a whole number of IRLs can be observed at any LOD threshold in an actual genome-scan experiment, the P = 0.05 limit trace shows individual points instead of a continuous line.
|
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
Table 3 gives details of three additional loci with some evidence for linkage detected in the young AAD families. These occurred on chromosomes 8q21.13 and 21q22 in the L55 subset and chromosome 22q11 in the L45 subset.
|
|
Performing ordered subset analyses on the loci identified by adding in families from old to young did not reveal any significant results (at P < 0.05; data not shown).
Numbers of observed and expected loci.
We next used the locus-counting approach to compare the number of observed loci in the age-stratified subsets with the number of loci that would be expected under the null hypothesis of no linkage, across all LOD score thresholds >0.59. This complements the analyses in which a nominal LOD score threshold is used to highlight regions of linkage. Results are shown in Fig. 1AC. The 245 L55 families produced significantly more loci than expected under the null hypothesis of no linkage across most of the LOD score thresholds from 0.593.0 (P < 0.01 over much of the range of LOD scores) (Fig. 1B). In the 39 L45 families, the number of observed loci exceeded only the number expected for LOD scores >2.0 (Fig. 1A). In contrast to the results in the younger-onset families, the G55 subset did not show any more regions of linkage than expected by chance (Fig. 1C).
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
For all seven loci with evidence for linkage in the overall genome-wide scan of 573 families, the LOD score was higher in the L55 subset than the G55 subset. Of these seven loci, five were detectable (at LODs >1.18, nominal P < 0.01) in the L55 subset, namely 1q24-25, 5q13, 8p21-22, 8q24.2, and 10q23.2. In contrast, only one locus highlighted in the overall scan (8p21-22) was detected in the G55 subset. In addition, our results provide evidence for novel loci on chromosomes 8q21, 21q22, and 22q11.
For the loci identified in the L55 subset, on chromosomes 8q24.2, 10q23.2, and 21q22, young families provide significantly more evidence for linkage than would be expected if the contribution to these loci were proportionate across all 573 families.
In the L45 subset, two loci (5q32 and 22q11) were identified above the nominal cutoff of LOD >1.18. One of these loci (5q32) occurs in the overall genome-wide scan of 573 families. For both these loci, both permutation analyses and ordered subset analyses supported a role for a small number of the youngest AAD families contributing disproportionately to the evidence for linkage.
In our study, families segregating young-onset type 2 diabetes provide more evidence for linkage than expected under the null hypothesis of no linkage, even though no loci individually reach genome-wide levels of significance. For example, in the L55 subset, we saw significantly (P = 0.01) more loci across the whole LOD score threshold range of 0.593.0 than expected by chance. For the L45 subset, only loci at the higher end of the LOD score range (LOD >2.0) were observed in significant excess. In contrast, the G55 subset yielded no more evidence for linkage than that expected by chance under the null hypothesis of no genetic predisposition. This suggests families with subjects diagnosed at older ages have reduced power to detect linkage, which raises the question as to whether these families have any genetic component to their diabetes or whether their etiology is entirely environmental. We would argue that there is at least some genetic component in older families but that the genes involved may have too small an effect to be detected by linkage. It is well known that the detection of linkage is very sensitive to the relative risk associated with the locus and that most genome scans operate close to the limits of detection for loci of modest effect. For example our genome scan of 573 families had 76 and 55% power to detect loci of
values of 1.37 and 1.28, respectively (6). This is not sufficiently powerful to detect the predisposing variants described to date, such as the E23K variant in the KCJN11 gene (Kir6.2) that predisposes to diabetes with an odds ratio of 1.23 (1.121.36) (12). In our large studies, the frequency of the predisposing K allele was very similar (40%) across all type 2 diabetes cases, regardless of AAD (10).
Results from previous genome scans of type 2 diabetes indicate that there is no one major predisposing locus in type 2 diabetes (6,1320). Our results confirm that this is also the case in subjects affected at young ages: it is not possible to conclude which linkage signals are real susceptibility loci and which occur by chance. To gain a better understanding of which loci are likely to be real, we compared our results to those of other genome scans. The presence of replication across populations adds weight to the body of evidence for that locus. Of the loci in our study, those on chromosomes 1q24-25 and 8p21-22 have been observed in several other studies and noted before (6,17,19). In addition, a locus on chromosome 5q35 has been identified with a heterogeneity-LOD score of 1.37 in a study of 14 maturity-onset diabetes of the young (MODY) families (21) and with a nonparametric LOD score of 2.1 in 26 early-onset (≥2 members diagnosed ≤45 years) Scandinavian families. There were, however, three families in both the MODY and Scandinavian studies. These regions are close enough to our peak that they could represent the same gene. The locus recently identified on 5q in a large French family is likely to be too proximal to represent the same gene (22).
Other genome-wide scans of type 2 diabetes families have included analyses by young AAD. Unlike our study, however, none has shown that most of the evidence for linkage across the genome comes from the younger-onset subjects. Ghosh et al. (5) performed ordered subset analyses on regions identified in a total genome scan of 719 Finnish sibpair-based type 2 diabetic families (index case diagnosed 3560 years). This showed that the 74 youngest AAD families provided increased evidence for linkage to a region on chromosome 6 (nominal P = 0.041 at 104.5 cM). A recent study of 472 Ashkenazi Jewish type 2 diabetic sibpairs also used ordered subset analysis to dissect identified loci but did not find any evidence for heterogeneity (20).
Other studies have focused exclusively on younger subjects. These include genome-wide scans in French (19), Utah Caucasian (17), and Scandinavian (23) type 2 diabetic families. Results from the well-replicated locus on 1q21-24 are particularly noteworthy. Subjects from the French and Utah Caucasian families linked to 1q were diagnosed on average at the relatively young ages of 49.5 and 50.6 years, respectively. In addition, in the Pima Indian genome scan (15), the evidence for linkage at this locus is increased in a subset of 55 sibpairs diagnosed <25 years.
It is not known whether subsetting by AAD and reassessing the evidence for linkage across the whole genome in other populations will produce similar results to ours. Such analyses will depend on the initial ascertainment criteria for the collection of families, ethnicity, and data on when collections and diagnoses were made. It is likely that the more affected family members ascertained, the lower the AAD compared with a general type 2 diabetic population. Therefore, if the initial collection focused on younger subjects or larger families, there may not be much value in further stratification by young AAD. Different age cutoffs may be required in non-Caucasian populations as the AAD is generally lower compared with Caucasians. In addition, the prevalence of type 2 diabetes is increasing in young people due to changes in obesity and physical activity, which may mean even younger ages at diagnosis are needed to pull out the families who are most powerful for mapping genetic risk factors by linkage. Finally, it is possible that AAD may be a surrogate for other traits, such as insulin resistance or BMI, that are more apt to produce the optimum subset for detecting genes by linkage. Despite these caveats, we would argue that analyses by AAD are needed. Our results and the consistent finding that young-onset type 2 diabetic subjects have an increased family history provide a good a priori hypothesis that younger subjects will provide the strongest evidence for linkage. This could both increase the evidence for loci already identified and provide evidence for novel loci specific to younger-onset subjects
In conclusion, families segregating young-onset type 2 diabetes provide disproportionate evidence for linkage in our U.K. Caucasian genome-wide scan. Younger subjects provide both a disproportionate amount of evidence for linkage to previously identified loci and evidence for additional loci. This suggests that, at least in Caucasian populations, efforts to define type 2 diabetes genes by linkage may be more powerful if focused on young AAD subjects.
![]() |
ACKNOWLEDGMENTS |
---|
We thank all of the patients, nurses, and doctors who contributed to the Diabetes UK Warren 2 collection.
Address correspondence and reprint requests to Prof. Mark McCarthy, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Site, Old Road, Headington, Oxford OX3 7LJ, U.K. E-mail: mark.mccarthy{at}drl.ox.ac.uk
Received for publication January 6, 2003 and accepted in revised form April 11, 2003
AAD, age at diagnosis; G55, AAD >55 years; IRL, independent regions of linkage; LOD, logarithm of odds; L45, AAD <45 years; L55, AAD <55 years
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|